Indication: 1. Primary hypercholesterolemia and mixed hyperlipidemia, to reduce elevated TC, LDL-C, ApoB and TG levels. 2. Patients with hypercholesterolemia and risk of atherosclerosis.

Indication: 1. Hypercholesterolemia Patients with primary hypercholesterolemia, including familial hypercholesterolemia (heterozygous type) or mixed hyperlipidemia (equivalent to type IIa and IIb of Fredrickson classification), can use this product to treat elevated total cholesterol, elevated low-density lipoprotein cholesterol, elevated apolipoprotein B and elevated triglycerides if dietary therapy and other non-drug treatments are unsatisfactory. In patients with homozygous familial hypercholesterolemia, atorvastatin calcium can be used in combination with other lipid-lowering therapies (such as LDL plasma dialysis) or alone (when no other treatment is available) to lower total cholesterol and low-density lipoprotein cholesterol. 2. Coronary heart disease Coronary heart disease or coronary heart disease-related critical illnesses (such as diabetes, symptomatic atherosclerotic disease, etc.) combined with high

Indication: Used to treat hypercholesterolemia and mixed hyperlipidemia; prevent and treat coronary heart disease and cerebral stroke.

Indication: Clinically applicable to the prevention and treatment of angina pectoris caused by coronary heart disease, especially variant angina pectoris and angina pectoris caused by coronary artery spasm. Applicable to various types of hypertension, and also has good efficacy on refractory and severe hypertension. Raynaud's syndrome. Because it can reduce afterload, it also has good efficacy on refractory congestive heart failure and is suitable for long-term use. In addition, it is also suitable for patients with angina pectoris suffering from obstructive respiratory diseases, and its efficacy is better than beta-receptor blockers.

Indication: Used for hyperlipidemia; suitable for patients with severe type IV or V hyperlipoproteinemia, high risk of coronary heart disease and those who have not responded to diet control, weight loss and other treatments; also suitable for patients with type IIb hyperlipoproteinemia, high risk of coronary heart disease and those who have not responded to diet control, weight loss and other blood lipid regulating drugs; in view of the potential carcinogenicity of this product to humans, its use should be strictly limited to the specified indications, and the drug should be discontinued promptly if the therapeutic effect is not obvious.